Efalizumab-associated thrombocytopenia.

Area of Science:

• Immunology
• Dermatology
• Hematology

Background:

• Efalizumab is a medication used to treat psoriasis.
• Thrombocytopenia has been reported as an adverse effect of efalizumab therapy.
• Current guidelines recommend monthly platelet counts for the first 3 months, then quarterly.

Observation:

• A case of efalizumab-associated thrombocytopenia occurred between 10 and 16 weeks of therapy.
• This observation suggests that thrombocytopenia may occur later in the treatment course than previously recommended monitoring intervals suggest.

Findings:

• Based on a case report and literature review, a revised monitoring protocol is proposed.
• The revised protocol recommends monthly platelet counts for the initial 4 months of efalizumab therapy.
• It also suggests resuming monthly counts if a significant drop (≥50 x 10(9) cells/L) occurs between counts and emphasizes patient education on thrombocytopenia signs/symptoms.

Implications:

• The findings suggest a need to adjust monitoring guidelines for efalizumab therapy to improve patient safety.
• Early detection and intervention for efalizumab-induced thrombocytopenia can mitigate potential complications.
• Enhanced patient education regarding the risks and symptoms of thrombocytopenia is crucial for effective management.